Related Experiment Videos
Bioequivalence of controlled-release calcium antagonists
R Schall1, F R Müller, F O Müller
1FARMOVS Research Centre for Clinical Pharmacology and Drug Development, Department of Pharmacology, University of the Orange Free State, Bloemfontein, South Africa. GNFMRS@FRM.UOVS.AC.ZA
Clinical Pharmacokinetics
|January 1, 1997
Summary
Published bioequivalence studies for controlled-release calcium antagonists often lack proper statistical analysis and methodological rigor. Many studies fail to meet requirements for pharmacokinetic variables, leading to unreliable conclusions on drug equivalence.
Area of Science:
- Pharmacokinetics
- Drug Development
- Regulatory Science
Background:
- Published bioequivalence studies for controlled-release calcium antagonists exhibit significant deficiencies.
- Conclusions from these studies should be interpreted with caution due to methodological and statistical shortcomings.
Purpose of the Study:
- To review and highlight the deficiencies in published bioequivalence studies for controlled-release calcium antagonists.
- To emphasize the importance of proper statistical analysis and methodological standards in bioequivalence assessments.
Main Methods:
- Review of published bioequivalence studies focusing on controlled-release calcium antagonists.
- Analysis of statistical methods, pharmacokinetic variable assessment, and study designs (single-dose vs. multiple-dose, fed vs. fasted conditions).
Main Results:
- Many studies lack proper statistical analysis, such as the calculation of 90% confidence intervals for pharmacokinetic variables.
- Inadequate assessment of key pharmacokinetic parameters like Cmax, tmax, and %PTF.
- Insufficient use of multiple-dose studies and fed condition assessments, which are crucial for controlled-release formulations.
Conclusions:
- A significant number of published bioequivalence studies for controlled-release calcium antagonists are methodologically flawed and statistically inadequate.
- These deficiencies compromise the reliability of reported bioequivalence conclusions.
- There is a critical need for adherence to established guidelines and comprehensive study designs to ensure accurate bioequivalence assessments for these drugs.